Last $6.93 USD
Change Today -0.93 / -11.83%
Volume 1.4M
POZN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

pozen inc (POZN) Snapshot

Open
$7.70
Previous Close
$7.86
Day High
$7.70
Day Low
$6.55
52 Week High
04/25/14 - $9.73
52 Week Low
08/21/13 - $4.03
Market Cap
213.8M
Average Volume 10 Days
263.4K
EPS TTM
$-0.27
Shares Outstanding
30.9M
EX-Date
12/31/13
P/E TM
--
Dividend
--
Dividend Yield
25.25%
Current Stock Chart for POZEN INC (POZN)

Related News

No related news articles were found.

pozen inc (POZN) Related Businessweek News

No Related Businessweek News Found

pozen inc (POZN) Details

POZEN Inc., a pharmaceutical company, develops products for the treatment of acute and chronic pain, and pain related conditions in the United States and internationally. Its primary PA product candidates comprise PA32540 and PA8140 for secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, which have completed clinical development in the United States. The company’s products also include Treximet for acute treatment of migraine attacks with or without aura in adults; and VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing non-steroidal anti-inflammatory drugs (NSAID)-associated gastric ulcers. It has collaborations with GlaxoSmithKline for the development and commercialization of proprietary combinations of a triptan and a long-acting NSAID; and Sanofi US for the commercialization of PA product candidates, as well as with AstraZeneca AB. The company was founded in 1996 and is headquartered in Chapel Hill, North Carolina.

16 Employees
Last Reported Date: 03/6/14
Founded in 1996

pozen inc (POZN) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $591.9K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $353.1K
Chief Medical Officer
Total Annual Compensation: $372.0K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $339.8K
Compensation as of Fiscal Year 2013.

pozen inc (POZN) Key Developments

POZEN Inc. Announces FDA Acceptance of Refiling of New Drug Application for PA8140/PA32540 Tablets

POZEN Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review, the resubmission of the New Drug Application (NDA) for PA8140/PA32540. The FDA also indicated the NDA would be treated as a Class 2 resubmission; therefore, the new user fee goal date is December 30, 2014. Issues raised during an audit of the manufacturing facility producing an active ingredient used in the manufacture of the products were the only deficiencies noted in the Complete Response Letter (CRL) POZEN received on April 25, 2014. If such inspection deficiencies are not satisfactorily addressed by the new user fee goal date, the FDA could issue another CRL. POZEN has agreed substantively to FDA's most recent draft product labeling.

POZEN Inc. Resubmits New Drug Application for PA8140/PA32540 to the U.S. Food and Drug Administration

POZEN Inc. announced that it has resubmitted the new drug application (NDA) for PA8140/PA32540 to the U.S. Food and Drug Administration (FDA). In accordance with the regulations, FDA is expected to notify POZEN within 14 days of receipt of the NDA whether or not the submission will be accepted, and if accepted, what the new PDUFA date will be.

Pozen Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2014; Provides Earnings Guidance for 2014

Pozen announced unaudited earnings results for the first quarter ended March 31, 2014. For the period company reported total revenue of $7.5 million in this first quarter this year, up from $1.4 million in the first quarter last year and net income attributable to common stockholders of $2.9 million or $0.09 per basic and diluted share against net loss attributable to common stockholders of $5.8 million or $0.19 per basic and diluted share a year ago. The company reported that it expects to be profitable for the year, based upon current projections.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
POZN:US $6.93 USD -0.93

POZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,361 GBp -31.00
Endo International PLC $66.97 USD -1.56
GlaxoSmithKline PLC 1,415 GBp -8.50
Merck & Co Inc $57.97 USD -0.18
Sunesis Pharmaceuticals Inc $6.69 USD -0.01
View Industry Companies
 

Industry Analysis

POZN

Industry Average

Valuation POZN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.7x
Price/Book 11.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact POZEN INC, please visit www.pozen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.